FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy
Related Topics >> Oracea | MediGene | Galderma

MediGene sells European rights to Oracea

July 31, 2008 — 10:15am ET | By John Carroll
Tools

MediGene has sold the European rights to Oracea for rosacea to Galderma Laboratories for €8 million upfront and up to €32 million in total based on certain commercialization milestones. Release

Be the first to comment
More stories about Oracea   MediGene   Galderma  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 48 + 12?
To combat spam, please solve the math question above.